FDAnews Drug Daily Bulletin

Biogen to Acquire Biotech Firm

Feb. 16, 2012
Biogen Idec said it will pay $75 million upfront and as much as $487.5 million in future payments to acquire closely held biotechnology company Stromedix, which is working on a treatment for damaging scar tissue in the lungs and other organs.
The Wall Street Journal